Compare BioNTech SE - ADR (BNTX) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Prospect Capital Corporation — how do they compare? BioNTech SE - ADR trades at $92.8 (market cap $23.31B), while Prospect Capital Corporation trades at $2.27 (market cap $1.14B). The key difference: BioNTech SE - ADR is far larger — about 20.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 21.93% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | PSEC | |
|---|---|---|
Market Cap | $23.31B | $1.14B |
Sector | Health | Financials |
52-Week High | $119.34 | $3.05 |
52-Week Low | $83.89 | $2.11 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 21.93% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
